About Henrik Balle Boysen

This author has not yet filled in any details.
So far Henrik Balle Boysen has created 443 blog entries.

Information from HAE International

2020-01-24T18:02:29+01:00January 24, 2020|HAEi News|

Mr. Steen Bjerre, HAE International’s Director of Communications, has decided to leave the organization to pursue other opportunities. HAE International appreciates Steen’s efforts over the years – and wishes him the very best in his future endeavors. Henrik Balle Boysen, HAE International’s EVP and COO will take over Steen’s duties until a new person has [...]

EMA approval of new Ruconest facility

2020-01-21T16:18:30+01:00January 21, 2020|HAEi News|

Pharming Group N.V. has received European Medicines Agency (EMA) approval of a Type II Variation for a new production facility for the Ruconest. With the addition of this new facility, Pharming will significantly increase the production capacity of Ruconest as it becomes fully operational over the coming year. Pharming is now also able to release [...]

KalVista updates on oral treatment

2020-01-13T13:48:30+01:00January 13, 2020|HAEi News|

“Based upon the progress of the ongoing KVD900 Phase 2 clinical trial, we expect to announce data from that trial in the second quarter of this year,” says Andrew Crockett, CEO of KalVista Pharmaceuticals, Inc. “We are also pleased to announce the selection of KVD824 for development as an oral prophylactic treatment for HAE. Based [...]

Regenxbio expects selection of lead product candidate in 2020

2020-01-13T08:59:48+01:00January 13, 2020|HAEi News|

As first announced in July 2019, Regenxbio Inc. is developing a one-time gene therapy candidate to deliver a gene encoding a therapeutic antibody against plasma kallikrein, a key protein of the plasma contact pathway which is left unregulated in patients with HAE. Preclinical animal studies conducted using NAV AAV8 indicate the potential for a sustained [...]

News from Canada

2020-01-03T13:09:33+01:00December 30, 2019|Canada|

From Executive Director Peter Waite, Canadian Hereditary Angioedema Network: The Canadian Hereditary Angioedema Network has updated its 2014 Canadian Hereditary Angioedema Guideline with an expanded scope to include the management of HAE patients worldwide. It is a collaboration of Canadian and international HAE experts and patient groups led by the Canadian Hereditary Angioedema Network. The objective of this guideline is to provide evidence-based recommendations, [...]

News from Cuba

2020-01-03T13:16:48+01:00December 30, 2019|Cuba|

From HAE patient Rosa María Perez: Epinephrine, Hydrocortisone, Prednisone, Benadryl ... with every health crisis there is a bombardment of medicines with which nothing is resolved. The edema was quick – “in crescendo” – until it reached a limit when it stopped, and then slowly began to decrease. Pediatricians and allergists agreed that it was an allergic process – allergy [...]

News from the United States of America

2020-01-03T13:17:25+01:00December 30, 2019|United States of America|

From Ianice Viel, Patient Advocate and Social Media Manager It’s with tremendous gratitude that we wrap up an exciting year at the US HAEA filled with activities that brought us closer as a HAE family while continuing to push the boundaries on HAE discoveries, treatment, and care. We are now more committed than ever to help every HAE patient lead [...]

News from Brazil

2020-01-03T13:17:54+01:00December 30, 2019|Brazil|

From Raquel Martins, President of Abranghe - Angioedema Hereditário Brasil, HAE International has received the very good news that Takhzyro (Lanadelumab) is now approved in Brazil for the treatment of HAE. The approval comes from the Brazilian Health Regulatory Agency (Anvisa), the coordinator of the Brazilian Health Regulatory System. 25-28 September 2019 Abranghe participated in and promoted HAE at the XLVI Brazilian [...]

News from Japan

2020-01-03T13:18:17+01:00December 30, 2019|Japan|

From President Beverley Yamamoto, HAE Japan (HAEJ): HAEJ applied for the 3rd PASE Award from EFPIA (European Federation of Pharmaceutical Industries and Associations) – PASE is Patient Advocacy Support by EFPIA. HAEJ applied for a project on paediatric HAE to do a survey to identify patients and their treatment needs as well as to carry out focus groups with families and [...]

Go to Top